Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1980 1
1985 1
1998 1
1999 1
2000 6
2001 5
2002 4
2003 7
2004 12
2005 10
2006 19
2007 15
2008 15
2009 13
2010 15
2011 5
2012 1
2013 1
2014 4
2015 5
2016 1
2017 4
2018 4
2019 2
2020 6
2021 3
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Results by year

Filters applied: . Clear all
Page 1
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J; GO42144 Investigator and Study Group. Sacher A, et al. N Engl J Med. 2023 Aug 24;389(8):710-721. doi: 10.1056/NEJMoa2303810. N Engl J Med. 2023. PMID: 37611121 Free article. Clinical Trial.
Biobanking for better healthcare.
Riegman PH, Morente MM, Betsou F, de Blasio P, Geary P; Marble Arch International Working Group on Biobanking for Biomedical Research. Riegman PH, et al. Mol Oncol. 2008 Oct;2(3):213-22. doi: 10.1016/j.molonc.2008.07.004. Epub 2008 Jul 30. Mol Oncol. 2008. PMID: 19383342 Free PMC article. Review.
., Llombart-Bosch, A., Lombardo, C., Nilsson, K., Philip, T., Pierotti, M.A., Riegman, P., Saghatchian, M., Storme, G., Tursz, T., Verellen, D, 2008. ...An easier access to these samples for the scientific community is considered as the main bottleneck for research …
., Llombart-Bosch, A., Lombardo, C., Nilsson, K., Philip, T., Pierotti, M.A., Riegman, P., Saghatchian, M., Storme, G., Tursz, …
Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.
Lickefett B, Chu L, Ortiz-Maldonado V, Warmuth L, Barba P, Doglio M, Henderson D, Hudecek M, Kremer A, Markman J, Nauerth M, Negre H, Sanges C, Staber PB, Tanzi R, Delgado J, Busch DH, Kuball J, Luu M, Jäger U. Lickefett B, et al. Front Immunol. 2023 Dec 22;14:1303935. doi: 10.3389/fimmu.2023.1303935. eCollection 2023. Front Immunol. 2023. PMID: 38187393 Free PMC article. Review.
Research objectives and general considerations for pragmatic clinical trials of pain treatments: IMMPACT statement.
Hohenschurz-Schmidt DJ, Cherkin D, Rice ASC, Dworkin RH, Turk DC, McDermott MP, Bair MJ, DeBar LL, Edwards RR, Farrar JT, Kerns RD, Markman JD, Rowbotham MC, Sherman KJ, Wasan AD, Cowan P, Desjardins P, Ferguson M, Freeman R, Gewandter JS, Gilron I, Grol-Prokopczyk H, Hertz SH, Iyengar S, Kamp C, Karp BI, Kleykamp BA, Loeser JD, Mackey S, Malamut R, McNicol E, Patel KV, Sandbrink F, Schmader K, Simon L, Steiner DJ, Veasley C, Vollert J. Hohenschurz-Schmidt DJ, et al. Pain. 2023 Jul 1;164(7):1457-1472. doi: 10.1097/j.pain.0000000000002888. Epub 2023 Mar 22. Pain. 2023. PMID: 36943273 Free PMC article.
A gut microbial signature for combination immune checkpoint blockade across cancer types.
Gunjur A, Shao Y, Rozday T, Klein O, Mu A, Haak BW, Markman B, Kee D, Carlino MS, Underhill C, Frentzas S, Michael M, Gao B, Palmer J, Cebon J, Behren A, Adams DJ, Lawley TD. Gunjur A, et al. Nat Med. 2024 Mar;30(3):797-809. doi: 10.1038/s41591-024-02823-z. Epub 2024 Mar 1. Nat Med. 2024. PMID: 38429524 Free PMC article.
Hormonal therapy of endometrial cancer.
Markman M. Markman M. Eur J Cancer. 2005 Mar;41(5):673-5. doi: 10.1016/j.ejca.2004.12.008. Epub 2005 Jan 18. Eur J Cancer. 2005. PMID: 15763641 Review.
Second-line treatment of ovarian cancer with single-agent gemcitabine.
Markman M. Markman M. Semin Oncol. 2002 Feb;29(1 Suppl 1):9-10. doi: 10.1053/sonc.2002.31588. Semin Oncol. 2002. PMID: 11840414 Review.
In this population, where patients are often heavily pretreated prior to the administration of gemcitabine, an acceptable dose and schedule is 800 to 1,000 mg/m(2) weekly for 3 weeks, followed by a 1-week rest. The anticipated objective response rate in the platinum/taxane …
In this population, where patients are often heavily pretreated prior to the administration of gemcitabine, an acceptable dose and schedule …
162 results